The Women Choosing Surgical Prevention (WISP) Trial

Study Groups:

If you are found to be eligible to take part in this study, you will be assigned a study arm
based on the type of surgery you choose with your doctor. If you choose ISDO, you will be in
Group 1. If you choose RRSO, you will be in Group 2.

Group 1:

Surgery #1: Interval Salpingectomy (IS):

If you are in Group 1, the study doctor will discuss the salpingectomy surgery with you in
detail, including the risks and possible benefits. You will be asked to sign a surgical
consent form.

Most patients have salpingectomy performed as an outpatient procedure. This means that you
will likely go home the day of your surgery. If the study doctor plans to have you stay
overnight in the hospital for any reason, it will be discussed with you.

During the surgery, the inside of your abdomen will be looked at and both of your fallopian
tubes will be removed. If the study doctor finds anything during the surgery that may be
cancerous, a tissue sample or a complete ovary will be removed during surgery and tested. If
cancer is found, a gynecologic oncologist would perform your cancer surgery.

Post-Salpingectomy (IS) Follow-Up:

One (1) month (+/- 1 month) after surgery:

- If the doctor thinks it is needed, you may have a physical exam, including an exam of
your surgical incisions (wounds) and a review of any complications you may have had from
surgery. If you do not live near the hospital, this may be done by a local doctor. If
you are unable to visit a your study doctor, you will be contacted by phone.

- The pathology (tissue) results from your surgery will be discussed with you by phone
call or at the 1-month visit. If the results are benign (show no cancer), you will move
to the ovarian cancer assessment period below. However, if the results show cancer, the
study doctor will refer you to a gynecologic oncologist and you will move to the
Follow-Up Phase.

Six (6) months (+/- 3 months) after surgery:

°You will complete the quality-of-life questionnaires.

Ovarian Cancer Assessment Period:

Every year (+/- 3 months) until delayed oophorectomy (DO) surgery:

You will have a physical exam, including a pelvic exam. You will have a transvaginal
ultrasound to look at your ovaries. Blood (about 1 tablespoon) will be drawn for CA-125
testing. You will complete the quality-of-life questionnaires. You will review and sign the
Completion Oophorectomy Recommendation Form at least every other year with your study doctor.
This form will be provided to make sure you understand the current age recommendations to
have surgery to remove your ovaries (DO).

The yearly test results will be discussed with you.

If results are benign (no cancer), you will continue with the above yearly tests until you
and your doctor decide to have the Delayed Oophorectomy (DO) surgery. When you and your
doctor have decided for you to have DO surgery, you will have pre-oophorectomy tests.

Pre-Oophorectomy (DO) Tests:

- You will have a physical exam, including a pelvic exam.

- If the doctor thinks it is needed, blood (about 1 tablespoon) may be drawn for CA-125
testing.

- If the doctor thinks it is needed, you may have a transvaginal ultrasound to look at
your ovaries.

- You will complete the quality-of-life questionnaires

- You will complete the medical questionnaires if you have not completed 1 in over 5
years.

- If your doctor thinks it is needed, you may have other tests.

The study doctor will discuss the pre-surgery test results with you.

Surgery #2: Delayed Oophorectomy (DO):

If your pre-oophorectomy testing is normal, the study doctor will discuss the planned surgery
with you in detail, including the risks and possible benefits. You will be asked to sign a
surgical consent form.

Most patients have oophorectomy performed as an outpatient procedure. If the study doctor
plans to have you stay overnight in the hospital for any reason, it will be discussed with
you.

During the surgery, the inside of your abdomen will be looked at and both of your ovaries
will be removed. If the study doctor finds anything during the surgery that may be cancerous,
a tissue sample will be removed during surgery and tested. If cancer is found, a gynecologic
oncologist would perform your cancer surgery.

Post-Oophorectomy (DO) Follow-Up:

One (1) month (+/- 1 month) after surgery:

- If the doctor thinks it is needed, you may have a physical exam, including an exam of
your surgical incisions (wounds) and a review of any complications you may have had from
surgery. If you do not live near the hospital, this may be done by a local doctor. If
you are unable to visit your study doctor, you will be contacted by phone.

- The pathology results from your surgery will be discussed with you by phone call or at
the 1-month visit. If the results are benign (show no cancer), you will move to the
ovarian cancer assessment period below. However, if the results show cancer, the study
doctor will refer you to a gynecologic oncologist and you will move to the Follow-Up
Phase.

At 6 months (+/- 3 months), 1 year (+/- 3 months), and 2 years (+/- 3 months) after surgery,
you will complete the quality-of-life questionnaires.

Group 2:

Surgery: RRSO:

If you are in Group 2, the study doctor will discuss the surgery with you in detail,
including the risks and possible benefits. You will be asked to sign a surgical consent form.

Most patients have RRSO performed as an outpatient procedure. If the study doctor plans to
have you stay overnight in the hospital for any reason, it will be discussed with you.

During the surgery, the inside of your abdomen will be looked at and both of your ovaries and
fallopian tubes will be removed. If the study doctor finds anything during the surgery that
may be cancerous, a tissue sample will be removed during surgery and tested. If cancer is
found, a gynecologic oncologist would perform your cancer surgery.

Post-Surgery (RRSO) Follow-Up:

One (1) month (+/- 1 month) after surgery:

- If the doctor thinks it is needed, you may have a physical exam, including an exam of
your surgical incisions (wounds) and a review of any complications you may have had from
surgery. If you do not live near the hospital, this may be done by a local doctor. If
you are unable to visit your study doctor, you will be contacted by phone.

- The pathology results from your surgery will be discussed with you by phone call or at
the 1-month visit. If the results are benign (show no cancer), you will move to the
ovarian cancer assessment period below. However, if the results show cancer, the study
doctor will refer you to a gynecologic oncologist and you will move to the Follow-Up
Phase and complete a yearly questionnaire.

At 6 months (+/- 3 months), 1 year (+/- 3 months), and 2 years (+/- 3 months) after surgery,
you will complete the quality-of-life questionnaires.

Length of Study:

Your last study visit will be about 1 month after your ovaries are removed. You will continue
to complete questionnaires for as long as possible. You will be taken off study early if you
no longer want to participate or cancer is found before the IS or RRSO surgeries.

Follow-Up Phase:

You will be moved to the Follow-Up Phase if cancer is found after IS or RRSO surgery, or if
you have completed all the necessary quality-of-life questionnaires. You will complete a
yearly follow-up questionnaire for as long as possible.

This is an investigational study. At this time, the only surgery known to lower your risk of
ovarian cancer is RRSO. ISDO has not been previously studied and may not lower your ovarian
cancer risk. Your decision for any of these surgeries will be made with your doctor. You will
sign a separate consent form that will describe each of these surgeries and their risks in
more detail. ISDO is currently being used for research purposes at MD Anderson.

Up to 300 women will be enrolled in this multicenter study. Up to 45 may take part at MD
Anderson.

Inclusion Criteria:

1. Women must be >/= 30 and
2. Premenopausal women with a documented deleterious mutation in one of the following
ovarian cancer genes: BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6,
MLH1, PMS2, or EPCAM. (Please note: Menopause is defined as >/= 12 months of
amenorrhea. However, for those patients with >/= 12 months of amenorrhea who may be
pre-menopausal, levels of FSH, LH, and estradiol in the pre-menopausal range will be
acceptable).

3. Willing to undergo two surgical procedures (if participant chooses the ISDO arm)

4. Presence of at least 1 fallopian tube and 1 ovary. (Please note: Prior unilateral
salpingectomy is allowed; prior bilateral salpingectomy is not allowed)

5. Patients who have undergone a prior tubal ligation will be eligible.

6. Participants may have a personal history of non-ovarian malignancy, but must: a) be
without evidence of disease at enrollment b) remain premenopausal c) have completed
treatment (including surgery, chemotherapy, radiotherapy or hormonal therapy) >3
months prior to enrollment (other than non-melanoma skin cancer)

7. Willingness to return to the enrolling site for the study surgical procedures,
including pre-operative and post-operative care. (Patients in the ISDO arm must be
willing to return to the enrolling site for yearly ovarian cancer assessment)

8. Patients must understand that they will be permanently sterilized

Exclusion Criteria:

1. Women with a personal history of ovarian, fallopian tube, or primary peritoneal cancer

2. Current treatment with Tamoxifen or Aromatase Inhibitors

3. Medical comorbidities making surgery unsafe as determined by the patient's surgeon

4. Women who are pregnant or post-partum (within 3 months of delivery). -Patients are
deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound,
beta HCG, or best judgement of the investigator. Pregnancy testing is not required per
protocol to determine study eligibility -Women who become pregnant on the ISDO arm via
reproductive technology can remain on study. However, data collection will be
suspended during pregnancy and 3 months post-partum

5. Women with elevated levels of CA125 (>50) or transvaginal ultrasound suggesting
cancer, unless findings are consistent with endometriosis. CA125 and transvaginal
ultrasounds must be the most recent, but no older than 1 year from the date of
enrollment.

6. Inability to provide informed consent.

7. Inability to read or speak English.